Welcome to our dedicated page for Akebia Therapeutics SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Akebia Therapeutics, Inc. filings document the regulatory record of a commercial-stage biopharmaceutical company focused on kidney disease therapeutics. Its 8-K reports include quarterly and annual operating results, Vafseo® commercialization updates, pipeline disclosures, Regulation FD presentations, and material agreements tied to licensing, supply, and corporate facilities.
Akebia’s proxy materials describe board composition, committee assignments, director elections, executive compensation, equity plans, and shareholder voting matters. The filing record also covers governance changes, Nasdaq-listed common stock matters, risk and business disclosures related to commercial products, clinical programs, collaborations, lease obligations, and capital-structure activity.
Akebia Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the third quarter ended September 30, 2025 and recent business highlights. The company issued the press release on November 10, 2025, and attached it as Exhibit 99.1. The report clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished rather than filed under the Exchange Act, so it is not subject to Section 18 liability and will only be incorporated into other SEC filings if specifically referenced. Akebia’s common stock, par value $0.00001 per share, trades on The Nasdaq Capital Market under the symbol AKBA.
Akebia Therapeutics (AKBA) announced a strategic setback. After meeting with the U.S. Food and Drug Administration, the company did not reach alignment on the design of the VALOR clinical trial evaluating vadadustat for anemia in late-stage chronic kidney disease patients not on dialysis. As a result, Akebia does not plan to initiate VALOR and does not expect to pursue a broad U.S. label for Vafseo in non-dialysis dependent CKD.
This decision narrows the company’s near-term U.S. regulatory path for vadadustat in the non-dialysis setting and shifts focus away from a broad label expansion. The disclosure was made under Regulation FD and as an Other Event, highlighting its significance to the company’s clinical and commercial strategy.